BRAF and thyroid gland carcinoma: As a highly effective risk-predicting and molecular marker for PTC, genetic testing for BRAF V600E mutation combined with FNA may improve the diagnostic accuracy of thyroid cancer and help surgeons to develop more individualized treatment plans (Kim et al., 2013a; Rashid et al., 2020).